Holen Sie sich die Stockscreener-App
1.51
1.95%
-0.03
Medicinova Inc Aktie (MNOV) Neueste Nachrichten
MediciNova (NASDAQ:MNOV) Receives “Buy” Rating from D. Boral Capital - Defense World
MediciNova (MNOV) Analyst Rating Maintained at 'Buy' with $9.00 - GuruFocus
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - Nasdaq
MediciNova completes enrollment in phase 2b/3 ALS clinical trial - Investing.com
MediciNova Provides Update on COMBAT-ALS Study of MN-166 for Amyotrophic Lateral Sclerosis - Quiver Quantitative
MediciNova (NASDAQ: MNOV) fully enrolls 234-patient Phase 2b/3 ALS ALS trial, targets 2026 top-line data - Stock Titan
Is MediciNova Inc a good long term investmentTake Profit Strategies & Ride the Wave of Market-Beating Growth - earlytimes.in
Gainers Report: Can MediciNova Inc stock continue upward trendShare Buyback & Growth Focused Investment Plans - BỘ NỘI VỤ
Can MediciNova Inc. stock sustain free cash flow growthMarket Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
EBITDA per share of MediciNova, Inc. – TSE:4875 - TradingView
Can MediciNova Inc. stock continue upward trendJuly 2025 Price Swings & Verified Entry Point Signals - Newser
MediciNova (MNOV) Stock Analysis Report | Financials & Insights - Benzinga
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
MediciNova, Inc. (MNOV) 9.22% in After-hours: Amid Routine Trading - Stocks Telegraph
MediciNova Reports Significant Milestone in MN-001 Program Following Journal Publication on Cholesterol Efflux Mechanism - Quiver Quantitative
Message from the CEO to MediciNova Shareholders - GlobeNewswire
MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’ - MSN
Stocks of Medicinova Inc (MNOV) are poised to climb above their peers - Setenews
Is MediciNova Inc. stock attractive for growth ETFsPortfolio Gains Summary & Risk Controlled Swing Alerts - BỘ NỘI VỤ
Why MediciNova Inc. stock could benefit from AI revolutionWeekly Gains Summary & Entry Point Strategy Guides - BỘ NỘI VỤ
Market Moves: Why MediciNova Inc. stock could benefit from AI revolutionAnalyst Downgrade & Verified Entry Point Signals - BỘ NỘI VỤ
MediciNova (NASDAQ:MNOV) Stock Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Can MediciNova Inc. stock attract ESG capital inflowsPortfolio Return Summary & Weekly Stock Breakout Alerts - newser.com
Can MediciNova Inc. stock beat market expectations this quarterCPI Data & Weekly Breakout Stock Alerts - newser.com
Will MediciNova Inc. stock continue upward momentumJuly 2025 Gainers & Weekly Breakout Opportunity Watchlist - newser.com
Trend analysis for MediciNova Inc. this weekJuly 2025 Breakouts & AI Driven Stock Price Forecasts - newser.com
Will MediciNova Inc. stock maintain growth story2025 Top Decliners & Daily Profit Focused Screening - newser.com
What Fibonacci levels say about MediciNova Inc. reboundWeekly Trade Summary & Real-Time Sentiment Analysis - newser.com
What dividend safety score for MediciNova Inc. stockShort Setup & Real-Time Chart Breakout Alerts - newser.com
Is MediciNova Inc. stock a contrarian buy2025 Big Picture & Precise Entry and Exit Recommendations - newser.com
Applying big data sentiment scoring on MediciNova Inc.2025 Key Highlights & Smart Swing Trading Alerts - newser.com
MediciNova appoints former FDA official as clinical advisor By Investing.com - Investing.com Nigeria
MediciNova appoints former FDA official as clinical advisor - Investing.com
MediciNova, Inc. Appoints Dr. Christopher D. Breder as Clinical and Regulatory Advisor - Quiver Quantitative
MediciNova (NASDAQ: MNOV) names FDA expert Dr. Breder clinical and regulatory advisor - Stock Titan
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):